Health & Environmental Research Online (HERO)


Print Feedback Export to File
2752914 
Technical Report 
On the antisteatosic effects of S-adenosyl-L-methionine in various chronic liver diseases (multicenter study) 
Mazzanti, R; Arcangeli, A; Salvadori, G; Smorlesi, C; Di Perri, T; Et al 
1979 
IPA/79/352050 
Ther 
REF 17 
25-34 
English 
IPA COPYRIGHT: ASHP The antisteatosic effects of S-adenosyl-L-methionine (S-adenosylemthionine; ademetionine; I) were evaluated in 37 patients in a multicenter study comprising 16 cases of simple hepatic steatosis, 10 cases of active chronic hepatitis, 5 cases of persistent chronic hepatitis and 6 cases of cirrhosis of the liver. I was infused IV at a dose of 150 mg/day for 15 consecutive days. Laboratory analyses (liver biopsy, transaminase and gamma-glutamyl transferase activities, serum albumin and total proteins, bilirubin and bromosulfophthalein clearance) were performed before and after the treatment cycle. Administration of I was very well tolerated. Statistically significant improvements of nearly all parameters was observed in the hepatic steatosis group; liver biopsy showed that fatty degradation had disappeared completely in 3 cases and in other patients it was clearly reduced. In the other groups, including active and persistent chronic hepatitis, I treatment favorably influenced several parameters, including steatosis; bromosulfophthalein clearance in active and persistent hepatatis improved. However, the inflammatory and connective components of these forms were not changed by the treatment.